Pfizer Stock Rises After Reassuring 2025 Guidance -- WSJ

Dow Jones12-17

By Jared S. Hopkins

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the company faces pressure to improve performance.

The company forecast next year's revenue will come in at $61 billion to $64 billion, with sales from its Covid-19 vaccine and drug similar to those of 2024. Analysts polled by FactSet had projected full-year 2025 revenue of about $63 billion.

"I'm very optimistic that '25 will be a year of continuous commercial execution and R&D turnaround," Chief Executive Albert Bourla told analysts.

Pfizer shares rose Tuesday by more than 3%, to top $26.

The stock is down more than 50% since its record high in 2021. Activist investor Starboard Value took a stake in the company in October and called for Pfizer's board to hold management accountable.

In addition to giving guidance Tuesday for next year, Pfizer said it plans $500 million in further cost cuts, after completing a $4 billion cost-cutting program.

Chief Financial Officer Dave Denton said Pfizer was prioritizing paying down debt. He said there was flexibility for dealmaking that could help with long-term growth, but there would be no large transactions until at least 2026.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

December 17, 2024 10:08 ET (15:08 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492966784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492966784","market":"other","top_or_hot":-1,"title":"Pfizer Stock Rises After Reassuring 2025 Guidance -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Jared S. Hopkins \n</p>\n<p>\n     Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the company faces pressure to improve performance. \n</p>\n<p>\n     The company forecast next year's revenue will come in at $61 billion to $64 billion, with sales from its Covid-19 vaccine and drug similar to those of 2024. Analysts polled by FactSet had projected full-year 2025 revenue of about $63 billion. \n</p>\n<p>\n     \"I'm very optimistic that '25 will be a year of continuous commercial execution and R&amp;D turnaround,\" Chief Executive Albert Bourla told analysts. \n</p>\n<p>\n     Pfizer shares rose Tuesday by more than 3%, to top $26. \n</p>\n<p>\n     The stock is down more than 50% since its record high in 2021. Activist investor Starboard Value took a stake in the company in October and called for Pfizer's board to hold management accountable. \n</p>\n<p>\n     In addition to giving guidance Tuesday for next year, Pfizer said it plans $500 million in further cost cuts, after completing a $4 billion cost-cutting program. \n</p>\n<p>\n     Chief Financial Officer Dave Denton said Pfizer was prioritizing paying down debt. He said there was flexibility for dealmaking that could help with long-term growth, but there would be no large transactions until at least 2026. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 10:08 ET (15:08 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Rises After Reassuring 2025 Guidance -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Rises After Reassuring 2025 Guidance -- WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 23:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Jared S. Hopkins \n\n\n     Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the company faces pressure to improve performance. \n\n\n     ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1883839398.USD","symbol_name":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492966784","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492966784","pubTimestamp":1734448080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the company faces pressure to improve performance.The company forecast next year's revenue will come in at $61 billion to $64 billion, with sales from its Covid-19 vaccine and drug similar to those of 2024. Analysts polled by FactSet had projected full-year 2025 revenue of about $63 billion.\"I'm very optimistic that '25 will be a year of continuous commercial execution and R&D turnaround,\" Chief Executive Albert Bourla told analysts.Pfizer shares rose Tuesday by more than 3%, to top $26.The stock is down more than 50% since its record high in 2021. Activist investor Starboard Value took a stake in the company in October and called for Pfizer's board to hold management accountable.In addition to giving guidance Tuesday for next year, Pfizer said it plans $500 million in further cost cuts, after completing a $4 billion cost-cutting program.Chief Financial Officer Dave Denton s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4599":"减肥药","BK4007":"制药","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4588":"碎股","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4581":"高盛持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)"},"translate_title":"辉瑞股价在2025年指引令人放心后上涨——华尔街日报","themeId":"82d36a84b850c4ce90d704ad5a74f9ba","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"By Jared S. Hopkins \n\n\n     Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the company faces pressure to improve performance. \n\n\n     The company forecast next year's revenue will come in at $61 billion to $64 billion, with sales from its Covid-19 vaccine and drug similar to those of 2024. Analysts polled by FactSet had projected full-year 2025 revenue of about $63 billion. \n\n\n     \"I'm very optimistic that '25 will be a year of continuous commercial execution and R&D turnaround,\" Chief Executive Albert Bourla told analysts. \n\n\n     Pfizer shares rose Tuesday by more than 3%, to top $26. \n\n\n     The stock is down more than 50% since its record high in 2021. Activist investor Starboard Value took a stake in the company in October and called for Pfizer's board to hold management accountable. \n\n\n     In addition to giving guidance Tuesday for next year, Pfizer said it plans $500 million in further cost cuts, after completing a $4 billion cost-cutting program. \n\n\n     Chief Financial Officer Dave Denton said Pfizer was prioritizing paying down debt. He said there was flexibility for dealmaking that could help with long-term growth, but there would be no large transactions until at least 2026. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 10:08 ET (15:08 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492966784"}